Heron Therapeutics
HRTX
162 hedge funds and large institutions have $163M invested in Heron Therapeutics in 2023 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 46 increasing their positions, 54 reducing their positions, and 30 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
6.89% less ownership
Funds ownership: 97.4% → 90.51% (-6.9%)
8% less funds holding
Funds holding: 176 → 162 (-14)
15% less repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 54
43% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 30
44% less capital invested
Capital invested by funds: $289M → $163M (-$126M)
73% less call options, than puts
Call options by funds: $20K | Put options by funds: $75K
Top Buyers
| 1 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
+$5.01M |
| 2 |
TC
Tejara Capital
London,
United Kingdom
|
+$2.94M |
| 3 |
CC
Clearline Capital
New York
|
+$2.67M |
| 4 |
Renaissance Technologies
New York
|
+$2.04M |
| 5 |
O
OrbiMed
New York
|
+$2.01M |
Top Sellers
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$8.17M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$8.03M |
| 3 |
Millennium Management
New York
|
-$7.36M |
| 4 |
Walleye Capital
New York
|
-$2.11M |
| 5 |
Goldman Sachs
New York
|
-$1.87M |
HRTX Hedge Fund Activity: Q1 2023 in Review
162 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q1 2023, worth a combined $163M — down 44% from $289M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of HRTX and 17 opened new positions — a net loss of 13 holders — while 54 trimmed existing stakes and 46 added.
The largest buyer was Velan Capital Investment Management, adding an estimated $5.01M. The largest seller was Deep Track Capital, cutting an estimated $8.17M.
- 162 institutional investors held Heron Therapeutics (HRTX) as of Q1 2023, down from 176 in Q4 2022.
- Funds reported $163M of Heron Therapeutics stock for Q1 2023, down 44% quarter-over-quarter.
- 17 funds opened new Heron Therapeutics positions in Q1 2023 and 30 closed out, a net change of -13 holders.
- The largest Heron Therapeutics buyer in Q1 2023 was Velan Capital Investment Management, an estimated $5.01M added.
- The largest Heron Therapeutics seller in Q1 2023 was Deep Track Capital, an estimated $8.17M sold.
Based on aggregated 13F filings for Q1 2023.